JOSE RAMIRO LAGUNA / SHUTTERSTOCK.COM
Which patented drugs are losing their market exclusivity in 2015, and how will their makers cope? LSIPR takes a look at five of the biggest drugs to lose patent protection in the US this year.
The small molecules cliff will soon make way for the biologics cliff—a phenomenon that is predicted to come into effect around 2020—but before then, here are five drugs that will lose US patent protection this year, possibly having a major impact on their makers.
Patent expired on January 4
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
patent, Gleevec, Sanofi, Actavis, Avodart, Otsuka. Namenda